Call for Abstracts

LATE BREAKING ABSTRACTS
Submission deadline is Friday, March 17, 2017.
How to submit an Abstract

Please read the following instructions carefully in order to successfully submit an abstract via our online portal.

 

Step 1: Go to our online portal

Step 2: Login to the online portal

CUA Members: You received an email from the CUA Office with your username and password. Your profile will automatically be filled in for you.

Non-members: Please create a new profile. Make sure to fill in your disclosures, so you will not have to re-input them in the abstract submission process.

Step 2: Submit your abstract    

On your Dashboard click on “My Abstracts”. You will be prompted to fill in your disclosure form first. Once your form is complete, you can submit your abstract or even clone your abstract if you have multiple abstracts with similar co-authors and affiliations, to reduce submission times and improve accuracy. Before submitting an abstract, read the below guidelines carefully.

Please note, abstract submission and registration is now open!
All presenters, who are accepted, must register and pay to present their abstract,
therefore now you can complete both at the same time to
take advantage of the early bird pricing!

 

Submission Terms

  1. Abstracts must be written and presented in English.
  2. Submitted abstracts undergo a blind review by peer reviewers based on scientific merit and originality.
  3. While abstracts may be submitted as podium, moderated poster, or unmoderated poster presentation types, the Scientific Committee reserves the right to assign final presentation type in the best interest of the program.
  4. Multiple abstracts by the same authors based on the same study population or data may be disqualified without further consideration.
  5. The work covered by the abstract must not have been published as a manuscript before January 9, 2017.
  6. Abstracts that have been presented at a major urological meeting must be disclosed and the rationale for presentation at the CUA must be justified. This can be emailed directly to the Program Manager (leona@iseventsolutions.com).
  7. Trials in progress can be submitted, but please note the committee will review and take into account if the information is presentable or not with the data accumulated.
  8. In regards to production deadlines, as of April 3, 2017, all presenting authors must be registered and paid to keep their abstract in the program. Any changes to the presenting author will not be reflected in the CUAJ after this date. 
  9. Authors are responsible for proofreading their abstract before submitting, particularly with regard to general orthography, as well as author names/order and affiliations. CUAJ will edit all submissions for consistency and formatting.

Abstract Format

  • Title:
    • The title should clearly define the topic and contain no abbreviations.
    • There is a character limit of 200 characters including spaces.
    • Enter the title as you were writing a sentence, Only CAPITALIZE the first letter of the sentence and proper nouns, nothing else.
    • No punctuation at the end of the sentence UNLESS it is a question mark (?) or exclamation point (!)
    • No symbols are permitted; write out the name of the symbol (i.e. Save beta, alpha, etc.). You will be allowed to use symbols for the abstract body.
  • Body:
    • The size of the abstract is limited to 2000 characters including spaces (or approx. 400 words). This includes body of abstract only.
  • The body must contain 4 separate paragraphs: a) Introduction; b) Methods; c) Results; and d) Conclusions. The abstract should be informative and detailed.
  • Standard abbreviations may be used as follows: on first use, spell out the full term and follow with abbreviation in parentheses. Abbreviations can be used subsequently.
  • Use generic names of drugs.
  • It is NOT acceptable to state that "The results will be discussed." Inclusion of specific data is necessary for reviewers.
  • Indicate the major new findings of the study.
  • References: The references are to be cited in your abstract body. The reference(s) will be placed at the bottom of your abstract automatically after you cite in the “Body” section of the submission process. Cite references sequentially in the body after a punctuation mark.
    Example: Jones A, Smith R, Doe J, et al. AS in prostate cancer management. Can Urol Assoc J 2016;10:201-5
  • Study Groups/Acknowledgements: These will be noted at the bottom of your abstract only in the Annual Meeting Online Publication.
  • Images, Figures, Tables and Graphs:
    • To insert an image or figure, it must be inserted as a JPG, must be at least 300 dpi in resolution and measure at least 3.5 inches wide, or else it cannot be reproduced in the CUAJ.
    • To insert a table or graph, please upload the JPG in your submission in the “Figures” step AND THEN upload the original Word Document or Excel version in the “Related Documents” step during the abstract submission.
    • Reference to accompanying images/figures/tables/graphs must be made within the body of the abstracts (i.e. Patient demographics are listed in Table 1). Further, all tables/graphs must be titled and all images/figures must have a caption.
  • Authors:
    • Take care to list ALL authors in the relevant section of the submission site. Spell out completely the names of all authors using full first and last names. Middle name initials should be capitals with a period at the end of it. (i.e. Stephanie M. Smith)
    • Maintain consistency in author names on multiple abstracts to avoid duplication in the Author Index.
    • Affiliations (Department, Institution) should be spelled out in full.
  • Presenting Author: If the author(s) of the abstract is an employee(s) of, or has a financial relationship with, the commercial interest, which controls the content of the presentation, then he/she cannot be the presenting author. However, investigators responsible for research and development are permitted to present as long as they resolve their Conflict of Interest (COI) and as long as they are not employees of the commercial interest. In all printed publications the presenting author will be underlined.
  • Conflict of Interest and Disclosure Statement: This is required for the submitting author and the presenting author. It is the responsibility of the submitting author to collect this information.
  • Topic List: Authors must select an abstract topic (only one) from the provided list.
    • BPH/ HBP
    • Advances in Technology / percées technologiques
    • Endourology/Laparoscopy/Robotics/Technical advances in urology // Endo­urologie/Laparoscopie/Chirurgie assistée par robot/Avances techniques en urologie
    • GU Trauma / Traumatisme génito­urinaire
    • Improving Patient Relations / Amélioration des relations avec les patients
    • Infertility / Infertilité
    • Lower Urinary Tract Reconstruction / Reconstruction des voies urinaires inférieures
    • Training and Evaluation / Formation et Évaluation
    • Male/Female Pelvic Pain / Douleurs pelviennes chez l'homme/la femme
    • Neurogenic Bladder / Vessie neurogène
    • Oncology - Bladder 
/ Oncologie 
- Vessie
    • Oncology - General Oncology 

/ Oncologie 
- Oncologie Général
    • Oncology - Kidney & Ureter 

/ Oncologie: Rein et Uretère
    • Oncology - Other
/ Oncologie 
- Autre
    • Oncology - Penis/Testis/Urethra 

/ Oncologie : Pénis/Testicules/Urètre
    • Oncology - Prostate 

/ Oncologie 
- Prostate
    • Pediatric Urology / Urologie Pédiatrique
    • Penile Carcinoma / Carcinome pénien
    • Penile/Urethral Surgery / Chirurgie pénienne/urétrale
    • Practice Management/Communications // Gestion de la pratique/communications
    • Renal Transplantation / Transplantation rénale
    • Renal Tumours / Tumeurs rénales
    • Renovascular Hypertension / Hypertension rénovasculaire
    • Sexual Dysfunction / Dysfonction sexuelle
    • Stone Disease / Lithiases
    • Testes Carcinoma / Carcinome du testicule
    • Urinary Incontinence / Incontinence urinaire
    • Urological Infections (Includes STD and UTI) / infections urologiques (inclus MTS et IU)
    • Urothelial Tumours / Tumeurs urothéliales
    • Vaginal Reconstructive Surgery / Chirurgie de reconstruction vaginale
    • Voiding Dysfunction / Dysfonction mictionnelle
    • Miscellaneous/Other / Sujets divers/Autres

Conflict of Interest Disclosures for submitting author and presenting author

Prior to submitting an abstract the submitter must collect the following information from the presenting author (if he/she is not the presenter).


All Presenters and Planning Committee members must complete this form and submit to the Office of Education. Disclosure must be made to the audience whether you do or do not have a relationship with a commercial entity such as a pharmaceutical organization, medical device company, or a communications firm.

Q1. (Yes or No) I have/had an affiliation (financial or otherwise) with a pharmaceutical, medical device or communications organization. Complete the section below as it applies to you during the past two calendar years. Please indicate the commercial organization(s) with which you have/had affiliations, and briefly explain what connection you have/had with the organization. You must disclose this information to your audience.    

If Q1 is yes then list all the activities over the past years for each of the following items AND if the activity is concluded or ongoing.

  1. I am a Member of an Advisory Board or equivalent with a commercial organization
  2. I am a member of a Speakers bureau
  3. I have received payment from a commercial organization (including gifts or other consideration or ‘in kind’ compensation) 
  4. I have received grant(s) or an honorarium from a commercial organization.
  5. I hold a patent for a product referred to in the CME/CPD program or that is marketed by a commercial organization.
  6. I hold investments in a pharmaceutical organization, medical devices company or communications firm.
  7. I am currently participating in or have participated in a clinical trial within the past two years.

Q2. (Yes or No) I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. off-label use of medications).

If yes, you must declare all off-label use to the audience during your presentation.

Contact us

  • CUA CORPORATE OFFICE
    185 Dorval, Suite 401
    Dorval, QC
    H9S 5J9
    Canada
  • (514) 395-0376
    Fax (514) 395-1664

Keep me Posted

First Name
Could not find the language line "frm_error"
Last Name
Could not find the language line "frm_error"
City
Could not find the language line "frm_error"
Country
Could not find the language line "frm_error"
Email
Could not find the language line "frm_error"

Future Dates

  • 73rd CUA | June 23rd-26th, 2018
    HALIFAX, NS
  • 74th CUA | June 29th-July 2nd, 2019
    QUEBEC CITY, QC
  • 75th CUA | June 27th-30th, 2020
    VICTORIA, BC